ORIC-944 is a small molecule commercialized by ORIC Pharmaceuticals, with a leading Phase I program in Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ORIC-944’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for ORIC-944 is expected to reach an annual total of $12 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ORIC-944 Overview

ORIC-944 is under development for the treatment of metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and Diffuse Large B cell Lymphoma. The drug candidates is an imidazopyrimidine binder. It acts by targeting EED (polycomb protein EED). It is administered through oral route.

ORIC Pharmaceuticals Overview

ORIC Pharmaceuticals is clinical-stage oncology company focused on the discovery and development of novel therapies against treatment-resistant cancers. Its lead drug candidate ORIC-101, is a selective small molecule antagonist of the glucocorticoid receptor (GR), implicated in resistance to various treatment modalities such as chemotherapy, immunotherapy, and anti-hormonal therapy across a broad range of cell lines and tumor types. The company is funded by EcoR1 Capital, The Column Group, OrbiMed Advisors, Topspin Partners, Foresite Capital and Kravis Investment Partners. ORIC Pharmaceuticals is headquartered in South San Francisco, California, the US..

The operating loss of the company was US$78.9 million in FY2021, compared to an operating loss of US$74.2 million in FY2020. The net loss of the company was US$78.7 million in FY2021, compared to a net loss of US$73.7 million in FY2020.

For a complete picture of ORIC-944’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.